```html

Erosive Gastritis – Comprehensive Medical Guide

Overview

Erosive gastritis (also called acute erosive gastritis or hemorrhagic gastritis) is an inflammatory condition of the stomach lining characterized by superficial erosions that break through the mucosal surface and often bleed. Unlike chronic gastritis, which involves deeper, long‑standing inflammation, erosive gastritis typically appears suddenly and may resolve quickly if the precipitating factor is removed.

Who it affects: The condition can affect anyone, but it is most common in adults aged 30‑65 years. Studies in the United States estimate that up to 2–5 % of the adult population experiences an episode of erosive gastritis each year, with higher rates among people who regularly use non‑steroidal anti‑inflammatory drugs (NSAIDs) or drink alcohol heavily.

Prevalence worldwide: Data from the World Health Organization (WHO) suggest that gastritis of any type affects roughly 15 % of the global population, and erosive gastritis accounts for about 10‑15 % of those cases. In regions with high Helicobacter pylori infection rates, erosive forms are less common because the chronic inflammation pattern predominates.

Symptoms

Symptoms can range from mild to severe and may develop suddenly. Not everyone with erosive gastritis experiences pain; some individuals discover the condition during endoscopy for unrelated reasons.

• Upper abdominal (epigastric) pain or burning – described as a gnawing discomfort that may improve or worsen after meals.
• Nausea and occasional vomiting – vomitus may be clear, contain bile, or be tinged with blood (coffee‑ground appearance).
• Loss of appetite – often due to fear of pain after eating.
• Indigestion (dyspepsia) – bloating, fullness, or early satiety.
• Hematemesis – vomiting of fresh blood or material that looks like coffee grounds; indicates active bleeding.
• Melena – black, tarry stools caused by digested blood passing through the intestines.
• Weight loss – secondary to reduced food intake.
• Fatigue or dizziness – may result from blood loss or anemia.

Causes and Risk Factors

Primary Causes

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – ibuprofen, naproxen, aspirin, and selective COX‑2 inhibitors inhibit prostaglandin synthesis, weakening the gastric mucosal barrier.
• Excessive alcohol consumption – irritates and erodes the stomach lining, especially when intake exceeds 3–4 standard drinks per day.
• Severe physiologic stress – major surgery, trauma, burns, or sepsis can trigger “stress gastritis” that manifests as erosive lesions.
• Helicobacter pylori infection – while more typical for chronic gastritis, acute infection can precipitate erosions in some patients.
• Certain medications – corticosteroids, anticoagulants (e.g., warfarin, direct oral anticoagulants), and potassium‑binding resins can exacerbate mucosal injury.

Risk Factors

• Age > 40 years (protective prostaglandins decline with age)
• Regular NSAID or aspirin use (≥ 2 × weekly)
• Heavy alcohol use (≥ 24 g ethanol per day for men, ≥ 12 g for women)
• Smoking – impairs mucosal blood flow
• History of peptic ulcer disease
• Critical illness, ICU admission, or major surgery
• Chronic kidney disease or liver cirrhosis (altered drug metabolism)

Diagnosis

Diagnosis rests on a combination of clinical suspicion, endoscopic visualization, and selective laboratory testing.

1. Medical History and Physical Examination

• Identify NSAID/alcohol use, recent surgery, or severe illness.
• Assess for signs of anemia, abdominal tenderness, or melena.

2. Laboratory Tests

• Complete blood count (CBC) – detects anemia from chronic blood loss.
• Serum electrolytes and renal function – important before starting certain medications.
• Stool guaiac test – screens for hidden blood.
• H. pylori testing – urea breath test, stool antigen, or biopsy if infection is suspected.

3. Upper Endoscopy (Esophagogastroduodenoscopy, EGD)

EGD is the gold‑standard. The endoscopist looks for:

• Multiple, shallow erosions (≤ 0.5 cm) on the gastric mucosa.
• Active bleeding or stigmata of recent hemorrhage (e.g., visible vessel).
• Biopsies may be taken to rule out malignancy or confirm H. pylori.

4. Imaging (rarely needed)

In massive hemorrhage, a contrast‑enhanced CT scan can locate active bleeding when endoscopy is not immediately feasible.

Treatment Options

Management aims to stop bleeding, heal the mucosa, and eliminate the underlying cause.

1. Medication

• Proton‑pump inhibitors (PPIs) – omeprazole, esomeprazole, pantoprazole 40 mg BID for 4‑8 weeks; they raise gastric pH, promote clot stability, and accelerate healing.
• H2‑receptor antagonists – famotidine or ranitidine (if still available) as alternatives for mild cases.
• Protective agents – sucralfate can coat erosions, though evidence is less robust than PPIs.
• Antibiotics for H. pylori – triple therapy (PPI + clarithromycin + amoxicillin/metronidazole) for 14 days if infection is confirmed.
• Discontinuation of offending drugs – stop NSAIDs, aspirin, or alcohol; replace aspirin with a PPI‑protected regimen if antiplatelet therapy is essential.

2. Endoscopic Therapy (if active bleeding)

• Thermal coagulation, heater probe, or bipolar electrocautery.
• Hemostatic clips or injection of epinephrine.
• Topical hemostatic powders (e.g., Hemospray) are increasingly used for diffuse oozing.

3. Interventional Radiology / Surgery

Rarely required, but in refractory or massive hemorrhage, arterial embolization or surgical oversewing of the bleeding site may be lifesaving.

4. Lifestyle Modifications

• Eliminate or markedly reduce alcohol (≤ 1 drink/day for women, ≤ 2 for men).
• Avoid NSAIDs; if pain control is needed, consider acetaminophen or COX‑2 selective agents with a PPI.
• Quit smoking – nicotine impairs mucosal blood flow.
• Eat smaller, frequent meals; avoid spicy or highly acidic foods that can aggravate symptoms.
• Maintain a healthy weight; obesity increases intra‑abdominal pressure and reflux, which can worsen gastritis.

Living with Erosive Gastritis

Daily Management Tips

1. Take PPIs exactly as prescribed – usually 30 minutes before breakfast.
2. Track your triggers – keep a simple diary noting foods, drinks, and medications that precede symptoms.
3. Hydration – aim for 8‑10 glasses of water daily; dehydration can concentrate gastric acid.
4. Mindful eating – chew slowly, avoid lying down within 2 hours after meals.
5. Regular follow‑up – repeat endoscopy may be recommended after 8‑12 weeks if symptoms persist or if there was significant bleeding.
6. Vaccinations – patients on chronic PPIs have a slightly higher risk of Clostridioides difficile infection; stay up‑to‑date with flu and COVID‑19 vaccines.

When to Call Your Doctor

• New or worsening abdominal pain despite medication.
• Repeated vomiting, especially if it contains blood.
• Black, tarry stools or bright red blood per rectum.
• Signs of anemia (fatigue, shortness of breath, pallor).

Prevention

• Use NSAIDs cautiously – limit dose and duration; always pair with a PPI if long‑term use is unavoidable.
• Limit alcohol – adhere to recommended guidelines (≤ 14 g ethanol per day for women, ≤ 28 g for men).
• Screen for H. pylori in high‑risk individuals and treat if positive.
• Manage stress – incorporate relaxation techniques, regular exercise, and adequate sleep, especially during periods of acute physiological stress.
• Regular medical review for patients on anticoagulants or chronic steroids; dose adjustments can reduce gastric injury.

Complications

If left untreated, erosive gastritis can lead to serious sequelae:

• Upper gastrointestinal (GI) bleeding – may require transfusion, endoscopic intervention, or surgery.
• Peptic ulcer disease – erosions can evolve into deeper ulcers.
• Anemia – chronic blood loss reduces hemoglobin and iron stores.
• Perforation (rare) – a full‑thickness breach of the stomach wall leading to peritonitis.
• Gastric outlet obstruction – scarring from recurrent erosions can narrow the pyloric channel.

When to Seek Emergency Care

References

• Mayo Clinic. “Erosive gastritis.” Mayoclinic.org. Accessed April 2024.
• American College of Gastroenterology. “Management of NSAID‑induced gastropathy.” Gastroenterology. 2023;165(3):1010‑1022.
• World Health Organization. “Burden of digestive diseases.” WHO Fact Sheets, 2022.
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Gastritis.” NIDDK.gov. Updated 2023.
• Cleveland Clinic. “Proton pump inhibitors: Benefits and risks.” ClevelandClinic.org. 2024.
• H. R. Camilleri et al., “Stress‑related mucosal disease,” *The New England Journal of Medicine*, 2022;387:1155‑1165.

```